Evaxion Biotech (EVAX) presents EVX-01 data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
April 28, 2025 8:00 AM EDT80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision of Evaxions AI-Immunology platform in selecting therapeutically relevant vaccine targetsNew findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizationsThe ongoing phase 2 trial with EVX-01 remains on track for two-year data readout in the... More
